AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings
AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, shows a 22.46% potential upside with strong buy ratings from analysts, despite reporting negative EPS and free cash flow. The company's stock is performing well, trading at the upper end of its 52-week range, largely due to its promising immunology therapeutics pipeline, including Imsidolimab in Phase 3 development. While AnaptysBio presents a speculative investment due to its pre-revenue status and operational losses, its strategic collaborations and positive technical indicators suggest potential for significant gains for risk-tolerant investors.
AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP
GSA Capital Partners LLP significantly reduced its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 46.6% in the third quarter, while several other institutional investors, such as Assenagon Asset Management S.A., 683 Capital Management LLC, Soleus Capital Management L.P., JPMorgan Chase & Co., and Federated Hermes Inc., substantially increased their positions. AnaptysBio also announced a $100 million share repurchase program, indicating management's belief that the stock may be undervalued. Insider selling by Eric J. Loumeau and CEO Daniel Faga was also reported, alongside various analyst ratings and price target adjustments.
AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday
AnaptysBio (ANAB) is expected to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting $0.89 earnings per share. Wall Street maintains a "Moderate Buy" consensus rating with a target price of $66.89, supported by recent price target increases from firms like Wells Fargo and Barclays. The company has also initiated a $100 million stock repurchase program, indicating management's belief that the stock may be undervalued, while insider selling has been noted by the CEO and another insider.
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock
AnaptysBio (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the company's stock for $540,000 on February 11th, reducing his ownership by 43.79%. Following this transaction, Loumeau now owns 12,835 shares valued at approximately $693,090. The biotechnology company also recently announced a $100 million stock repurchase plan, indicating management believes the stock is undervalued.
ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline
AnaptysBio (ANAB) is set to separate its royalty and biopharma operations in Q2, aiming to unlock value from strong Jemperli royalty growth and a robust clinical pipeline. The company anticipates key clinical readouts and strategic decisions on cash allocation and partnerships throughout 2024. This move is expected to highlight the potential of both segments independently.
AnaptysBio stock hits 52-week high at $52.56 By Investing.com
AnaptysBio's stock reached a new 52-week high of $52.56, reflecting a 305.98% increase over the past year and a 151.2% return in the last six months. Investor confidence has been bolstered by recent advancements and strategic initiatives, including legal proceedings and partnerships. Analysts maintain a bullish outlook despite the company not being profitable in the last twelve months, with UBS initiating coverage with a Buy rating.
(ANAB) and the Role of Price-Sensitive Allocations
Anaptysbio Inc. (ANAB) shows strong sentiment across all horizons, indicating an overweight bias, with a breakout underway. Predictive AI models have generated distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term time horizons.
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week High - Should You Buy?
AnaptysBio (NASDAQ:ANAB) recently hit a new 52-week high of $56.39, closing at $53.90, with a market capitalization of $1.53 billion. Analysts have a "Moderate Buy" rating with an average price target of $66.89, despite recent insider selling totaling over $6.7 million and a substantial stock buyback authorization of $100 million by the board. The company's stock is currently trading above its 50-day and 200-day moving averages.
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts
AnaptysBio plans to separate into two publicly traded companies in Q2 2026: a biopharma company holding clinical programs and a royalty entity. The royalty company will focus on royalties from GSK's Jemperli and potential economics from Vanda's imsidolimab. The spun-out biopharma will advance programs like CD122 (ANB033), ANB101, and rosnilimab, with significant cash reserves to fund development into 2028.
AnaptysBio stock hits 52-week high at $52.56 By Investing.com
AnaptysBio Inc. (NASDAQ: ANAB) reached a 52-week high of $52.56, reflecting a 305.98% increase over the past year and 151.2% in the last six months. This surge is attributed to strategic initiatives and investor confidence, despite the company not being profitable in the past year. Analysts maintain a bullish outlook, with some setting targets as high as $140, citing the company's "GOOD" financial health and ongoing legal and collaborative developments.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts
AnaptysBio, Inc. (NASDAQ:ANAB) has received an average "Moderate Buy" recommendation from eleven brokerages, with a mean 12-month price target of $66.89. The company's board has authorized a $100 million share repurchase program, indicating they may view the stock as undervalued, despite recent insider selling of 146,280 shares worth approximately $6.7 million. AnaptysBio is a clinical-stage biotechnology company focused on therapeutic antibody product candidates in immunology and inflammation.
ANAB SEC Filings - Anaptysbio Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for AnaptysBio Inc. (ANAB) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries of these documents. Recent filings detail financial results, investor presentations, a potential two-company split, and insider trading activities. Investors can use this information to understand the company's financial health, strategic directions, and regulatory disclosures.
Anaptys Announces Participation at Upcoming Investor Conferences
AnaptysBio, Inc. announced that its president and chief executive officer, Daniel Faga, and other executive leadership members will participate in several investor conferences in February and March 2026. These conferences include the Guggenheim Emerging Outlook: Biotech Summit, Piper Sandler Virtual Novel Targets in Immunology Symposium, TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, UBS Biotech Summit Miami, and Leerink Global Healthcare Conference. The company will be presenting on its clinical-stage immunology therapeutics and its intent to separate its biopharma operations from its royalty assets by year-end 2026.
ANAB SEC Filings - Anaptysbio Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of AnaptysBio Inc. (ANAB) SEC filings, including 10-K, 10-Q, and 8-K forms, designed for investors and traders. It details recent insider transactions, such as RSU vestings and share sales for tax obligations, by the CMO and CLO, and also covers the company's expanded stock repurchase plan. The platform also offers AI-powered summaries of these filings to simplify complex regulatory information.
Anaptys Announces Participation at Upcoming Investor Conferences
AnaptysBio, Inc., a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences in February and March 2026. Company executives, including President and CEO Daniel Faga, will engage in fireside chats and one-on-one meetings to discuss their innovative immunology therapeutics pipeline. Live webcasts of the fireside chats will be available on the company's investor relations website.
Anaptys Announces Participation at Upcoming Investor Conferences
AnaptysBio, Inc. will participate in multiple investor conferences in February and March 2026, including the Guggenheim Emerging Outlook: Biotech Summit, Piper Sandler Virtual Novel Targets in Immunology Symposium, TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, UBS Biotech Summit Miami, and Leerink Global Healthcare Conference. The company's President and CEO, Daniel Faga, and other executive leadership team members will engage in fireside chats and 1x1 investor meetings to discuss their innovative immunology therapeutics pipeline and strategic plans, including the intent to separate biopharma operations from royalty assets.
Biotech firm Anaptys lines up February–March investor events
Anaptys (Nasdaq: ANAB) announced that its CEO, Daniel Faga, and other executives will participate in several investor conferences during February and March 2026. These events include Guggenheim, Piper Sandler, TD Cowen, Barclays, UBS, and Leerink, featuring fireside chats and one-on-one meetings. Live webcasts of the fireside chats will be available on the company's investor website, with replays for at least 30 days.
Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB
Federated Hermes Inc. significantly increased its stake in AnaptysBio, Inc. by 2,236.6% in Q3, now owning 193,327 shares valued at $5.92 million. Other institutional investors also made substantial purchases, indicating positive sentiment. AnaptysBio reported strong Q3 earnings, beating analyst estimates, and announced a $100 million share buyback program.
Responsive Playbooks and the ANAB Inflection
This article analyzes Anaptysbio Inc. (NASDAQ: ANAB), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 50.0:1 risk-reward short setup and provides AI-generated trading strategies for different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging strategies.
AnaptysBio (NASDAQ:ANAB) Downgraded to Buy Rating by Wall Street Zen
Wall Street Zen has downgraded AnaptysBio (NASDAQ:ANAB) from a "strong-buy" to a "buy" rating, despite the biotechnology company exceeding its recent quarterly EPS and revenue estimates. The consensus among analysts still rates ANAB as "Moderate Buy" with an average price target of $62.70, though some insiders have been selling shares. The company recently announced a $100 million stock buyback program, suggesting management believes the stock is undervalued.
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup
AnaptysBio (NASDAQ:ANAB) demonstrates a strong combination of high-growth momentum and a bullish technical setup, making it an attractive option for investors. The company exhibits exceptional revenue growth, significant EPS improvement, positive analyst revisions, and a history of beating earnings estimates, as indicated by its high ChartMill High Growth Momentum (HGM) Rating. Technically, ANAB shows a forceful uptrend, outperforming the market and its sector, and is currently in a high-quality consolidation pattern ripe for a potential upward move.
Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects
AnaptysBio (ANAB) is showing technical strength and improving profitability prospects, drawing investor attention despite a recent pullback. While its Price-to-Sales ratio of 7.6x appears overvalued compared to peers and fair value, a Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued, trading 78% below its estimated future cash flow value. Investors should consider both perspectives and associated risks.
CD122’s double whammy makes for intriguing target
Anaptysbio Inc. is focusing on CD122, a shared beta subunit of the IL-15 and IL-2 receptors, for drug development. The company plans to release phase Ib results for ANB-033 in celiac disease during Q4, with potential future studies targeting eosinophilic esophagitis. This dual-target approach makes CD122 a promising candidate for inflammatory disease treatment.
Understanding the Setup: (ANAB) and Scalable Risk
This article provides an in-depth analysis of Anaptysbio Inc. (NASDAQ: ANAB), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details various AI-generated trading strategies—Long, Momentum Breakout, and Short—with specific entry, target, and stop-loss levels. The analysis emphasizes risk-reward ratios and multi-timeframe signal analysis to guide trading decisions.
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative?
AnaptysBio (ANAB) recently presented at the J.P. Morgan Healthcare Conference, highlighting significant year-over-year improvements in EPS and revenue, alongside increased analyst forecasts. While the company's antibody platform and buyback authorization attract attention, risks such as ongoing unprofitability, insider selling, and a rising CEO pay package despite losses persist. Analysts currently estimate a fair value of US$66, suggesting the stock remains potentially undervalued despite these mixed signals.
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative?
AnaptysBio (ANAB) recently presented at the J.P. Morgan Healthcare Conference, highlighting significant year-over-year improvements in EPS and revenue, alongside increased analyst forecasts. This high-profile appearance and strong financial reporting are reshaping the company's investment narrative, despite ongoing challenges such as unprofitability, negative equity, and insider selling. Investors are encouraged to assess the company's potential undervaluation and clinical pipeline progress against these risks.
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative?
AnaptysBio recently improved its earnings per share and revenue significantly, drawing attention at the J.P. Morgan Healthcare Conference. Despite these gains and a stock buyback program, the company faces ongoing losses, balance sheet pressure, and insider selling. Investors are weighing the potential of its antibody platform against these risks.
Anaptysbio director Marquet sells $530k in shares
AnaptysBio director Marquet Magda sold 11,000 shares of common stock totaling $530,531 on January 15, 2026, while also exercising options to acquire 11,000 shares. The sales occurred after the company's shares surged 208% over the past year, trading near its 52-week high. The article also notes recent positive developments for AnaptysBio, including reiterations of "Buy" ratings and a legal dispute with GSK.
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment
ANAPTYSBIO INC (NASDAQ:ANAB) aligns with Mark Minervini's investment strategy, showing strong technical health and fundamental improvement. The stock meets the Minervini Trend Template criteria, indicating a clear upward trend and outperforms the broader market, with a ChartMill Relative Strength score of 97.29. Fundamentally, ANAB demonstrates high growth momentum through significant year-over-year EPS and revenue increases, alongside a recent shift to profitability, making it a compelling candidate for high-growth momentum investors.
Anaptysbio director Marquet sells $530k in shares By Investing.com
Marquet Magda, a director at AnaptysBio Inc (NASDAQ:ANAB), sold 11,000 shares of common stock for a total of $530,531 on January 15, 2026. This transaction occurred after the company's stock surged 208% over the past year, trading near its 52-week high. Concurrently, Marquet exercised options to acquire 11,000 shares at a lower price.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages
Brokerages have given AnaptysBio, Inc. (NASDAQ:ANAB) a consensus "Moderate Buy" rating, with an average one-year target price of $60.40. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. AnaptysBio also announced a $100 million share repurchase plan, although insiders have sold a notable amount of shares in the past 90 days.
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares
AnaptysBio Director Magda Marquet sold 11,000 shares of ANAB stock for $530,530, reducing her stake by over 50%. This transaction occurred after AnaptysBio reported stronger-than-expected earnings and revenue but remained unprofitable, with the board also approving a $100 million share repurchase program. Analysts currently maintain a "Moderate Buy" rating for the stock with a consensus target price of $60.40.
Anaptysbio director Marquet sells $530k in shares By Investing.com
AnaptysBio Inc. director Marquet Magda sold 11,000 shares of common stock for over $530,000 on January 15, 2026, after the company's stock surged 208% over the past year. Marquet also exercised options to acquire 11,000 shares on the same day. Despite the sale, analysts maintain a "Strong Buy" consensus, with the company currently involved in litigation with GSK and benefiting from recent positive developments like a funding agreement with Royalty Pharma and Teva.
Anaptysbio director Marquet sells $530k in shares By Investing.com
AnaptysBio Inc. (NASDAQ:ANAB) director Marquet Magda sold 11,000 shares of common stock for over $530,000 on January 15, 2026. This transaction occurred after the shares experienced a 208% surge over the past year. The director also exercised options to acquire 11,000 shares at a lower price on the same day.
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3% - Time to Sell?
AnaptysBio (NASDAQ:ANAB) shares fell 7.3% despite a surprise quarterly beat and a $100 million share buyback authorization. The company remains unprofitable, with analysts forecasting negative EPS for the current fiscal year, and insiders have sold a significant number of shares recently. Analysts currently rate the stock a "Moderate Buy" with an average target price of $60.40.
ANAB Stock Price, Forecast & Analysis | ANAPTYSBIO INC (NASDAQ:ANAB)
This article provides a detailed analysis of AnaptysBio Inc. (NASDAQ: ANAB) stock, including its price, forecast, and various financial metrics. It highlights the company's strong short-term price performance and technical rating, alongside weaker fundamental scores in profitability and health. The report also includes analyst ratings, future growth expectations, and an overview of the company's biotechnology focus.
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2% - Time to Buy?
AnaptysBio (NASDAQ:ANAB) stock surged 7.2% intraday on light trading volume, reaching $47.88, following quarterly results that beat analyst expectations with $0.52 EPS versus -$1.06 expected and $76.3 million revenue against $15.8 million anticipated. Despite negative margins and a forecast of -6.08 EPS for the year, the company's board approved a $100 million share buyback program. Analysts currently maintain a "Moderate Buy" consensus rating with a $60.40 price target, though recent insider sales have been noted.
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation
UBS has reiterated its Buy rating on AnaptysBio (NASDAQ:ANAB) with a $70.00 price target, representing a 44% upside, despite the company's ongoing legal dispute with GSK. AnaptysBio is seeking to dismiss a breach of contract claim from GSK, with the next trial dated for July 2026. The company maintains a "GOOD" financial health score and has seen recent positive developments, including a funding agreement with Royalty Pharma and Teva.
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock
AnaptysBio's stock was boosted by a $500 million funding agreement between Royalty Pharma and Teva for the development of TEV-53408, an IL-15 monoclonal antibody. This deal is seen as a validation of the IL-15/CD122 axis, positively impacting investor perception of AnaptysBio’s ANB033. Analysts generally maintain a "Strong Buy" consensus for ANAB, with the stock trading slightly below its fair value.
What Investors Should Know About a $163K AnaptysBio Insider Sale
Paul F. Lizzul, AnaptysBio's chief medical officer, sold 3,650 shares for approximately $163,191.50. AnaptysBio is a clinical-stage biotechnology company focused on antibody therapeutics for inflammatory and immunological conditions. The company's stock shows an upward trend and is a strong favorite among the community, with a target price indicating a positive potential of 21.05%.
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock
Anaptysbio's Chief Medical Officer, Paul F. Lizzul, sold 3,650 shares of company stock for $163,191 to cover tax obligations related to Restricted Stock Units (RSUs) on January 8, 2026. Lizzul also exercised options on 8,525 shares through RSU conversion on January 7, 2026, and now directly owns 42,088 shares plus 25,575 RSUs vesting over four years. This comes amidst ongoing legal proceedings for AnaptysBio concerning royalties for the cancer drug Jemperli and recent analyst coverage with mixed price targets.
What AnaptysBio (ANAB)'s Royalty Spin-Off Plan Means For Shareholders
AnaptysBio (ANAB) plans to separate its biopharma operations from its royalty assets by the end of 2026, which could significantly alter its investment profile. This comes amidst ongoing litigation with Tesaro and concerns about the company's unprofitable biopharma engine, cash burn, and stock valuation. The separation aims to provide clearer insight into the distinct value drivers of its royalty portfolio versus its clinical and financing risks.
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock
Anaptysbio's Chief Medical Officer, Paul F. Lizzul, sold 3,650 shares worth $163,191 to cover tax obligations from RSU vesting. This follows his exercise of options on 8,525 shares. Lizzul now directly owns 42,088 shares and holds an additional 25,575 RSUs vesting annually.
Anaptysbio CLO Loumeau sells $98,809 in shares
Eric J. Loumeau, Chief Legal Officer of Anaptysbio (NASDAQ:ANAB), sold 2,210 shares worth $98,809 on January 8, 2026, after acquiring 5,888 shares through restricted stock unit exercise the previous day. This transaction occurs as ANAB shares have seen a 214% return over the past year and trade near their Fair Value, with analysts giving a bullish consensus and price targets up to $140. The company is also involved in ongoing legal disputes with Tesaro and GSK and has received varied analyst ratings from UBS (Buy, $70 target) and Stifel (adjusted $56 target).
Eric Loumeau Sells 2,210 Shares of AnaptysBio (NASDAQ:ANAB) Stock
Eric Loumeau, an insider at AnaptysBio (NASDAQ:ANAB), sold 2,210 shares of the company's stock on January 8th, reducing his holding by 14.69%. This sale, alongside other insider sales from the CEO and CFO, could put near-term pressure on the stock. Despite this, AnaptysBio recently beat EPS and revenue estimates, authorized a $100M share buyback, and received positive analyst coverage, including an upgrade from UBS.
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
AnaptysBio, Inc. has filed a motion to dismiss Tesaro's claim of anticipatory breach of contract in the Delaware Chancery Court amidst ongoing litigation between Anaptys, GSK, and Tesaro. The dispute centers on a Collaboration and Exclusive License Agreement entitling Anaptys to royalties from Jemperli sales, with Anaptys asserting Tesaro and GSK have materially breached the agreement. The trial for all claims is scheduled for July 14-17, 2026, and the court is expected to hear Anaptys’ Motion to Dismiss by early March.
Anaptysbio CFO Mulroy sells $86k in shares
Anaptysbio CFO Dennis Mulroy sold 1,908 shares of common stock for $86,069 on January 7, 2026, and also exercised options and was granted restricted stock units and options. The company is involved in ongoing litigation with Tesaro and GSK and has received varied analyst ratings, with UBS initiating a Buy rating and Stifel lowering its price target while maintaining a Buy. These events indicate active financial and strategic developments for AnaptysBio.
Paul Lizzul Sells 3,650 Shares of AnaptysBio (NASDAQ:ANAB) Stock
AnaptysBio insider Paul Lizzul sold 3,650 shares of NASDAQ:ANAB stock on January 8th for $163,191.50, reducing his position by nearly 8%. This clustered insider selling, which also includes the CEO and CFO, occurs amidst several positive developments for the company, such as a $100 million share buyback authorization, a partial motion to dismiss in a royalty dispute, and stronger-than-expected earnings. Analysts currently have a "Moderate Buy" rating on AnaptysBio with a consensus price target of $60.40.
AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute
AnaptysBio has filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court, stemming from a dispute over royalties for the cancer drug Jemperli. The company argues it never repudiated the agreement and only sought to assert its contractual rights. AnaptysBio's stock has seen significant price appreciation over the past year despite not being profitable, and analysts anticipate substantial sales growth.
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
AnaptysBio has filed a motion to dismiss Tesaro's claim of anticipatory breach of contract in Delaware Chancery Court. This action is part of ongoing litigation between Anaptys, GSK, and Tesaro regarding their Collaboration and Exclusive License Agreement, under which Anaptys is entitled to royalties from Jemperli sales. Anaptys asserts it has not repudiated the agreement and argues Tesaro's lawsuit is a strategic attempt to deter the assertion of Anaptys' legal rights.
